AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15551197 — intervention group
Group type: COMPARATOR
Intervention: Blind-randomized treatment with Paroxetine (PAROX) and Amitriptyline (AMI)
Number of subjects: 127
Study 11682575 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.5 pmol x kg(‐1) x min(‐1) from 30 to 180 minutes)
Number of subjects: 8
Study 11682575 — intervention group
Group type: COMPARATOR
Intervention: Control (glucose and insulin alone infusion)
Number of subjects: 8
Study 9502624 — intervention group
Group type: EXPERIMENTAL
Intervention: Saruplase (20-mg bolus and 60-mg infusion over 60 min)
Number of subjects: 3089
Study 9502624 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (1.5-MU infusion over 60 min)
Number of subjects: 3089
Study 9502624 — intervention group
Group type: EXPERIMENTAL
Intervention: Saruplase
Number of subjects: 3089
Study 9502624 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 3089
Study 9502624 — intervention group
Group type: EXPERIMENTAL
Intervention: Saruplase and Streptokinase
Number of subjects: 3089
Study 8044938 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (10 mg oral)
Number of subjects: 20
Study 8044938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8044938 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 20
Study 2904568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 100
Study 2904568 — intervention group
Group type: COMPARATOR
Intervention: Colloidal bismuth subcitrate (CBS) with placebo
Number of subjects: 100
Study 2904568 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) with tinidazole
Number of subjects: 100
Study 2904568 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine with tinidazole
Number of subjects: 100
Study 30208243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound simulator training (2 self‐directed practice ultrasound sessions over 4 weeks)
Number of subjects: 19
Study 30208243 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional access to a simulator or ultrasound training)
Number of subjects: 19
Study 30208243 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention practical examinations
Number of subjects: 19
Study 28219690 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year surveillance interval
Number of subjects: 1560
Study 28219690 — intervention group
Group type: COMPARATOR
Intervention: 5-year surveillance interval
Number of subjects: 1560
Study 25889313 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (OCT) 0.3 mg/day for 3 days
Number of subjects: 97
Study 25889313 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine butylbromide (SB) 60 mg/day for 3 days
Number of subjects: 97
Study 24063214 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine acupuncture combined speech training (Group B)
Number of subjects: 132
Study 24063214 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined language training (Group C)
Number of subjects: 132
Study 24063214 — intervention group
Group type: COMPARATOR
Intervention: Speech training (Group A)
Number of subjects: 132
Study 21859820 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 803
Study 21859820 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 803
Study 21859820 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX or FOLFIRI
Number of subjects: 803
Study 19093729 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1200 mg
Number of subjects: 28
Study 19093729 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid (ALA) 600 mg
Number of subjects: 28
Study 19093729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C(NAC))
Number of subjects: 28
Study 19093729 — intervention group
Group type: COMPARATOR
Intervention: Placebo (C(ALA))
Number of subjects: 28
Study 18020969 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin supplementation (2.5 mg folate, 0.5 mg vitamin B(12), 25 mg vitamin B(6))
Number of subjects: 47
Study 18020969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 18020969 — intervention group
Group type: EXPERIMENTAL
Intervention: B-vitamin supplementation in hyperhomocysteinemic subjects (HCY>15 mumol/L, n=8)
Number of subjects: 47
Study 15472638 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine stress in patients with extensive reversible perfusion defects (summed difference score > or =8)
Number of subjects: 86
Study 15472638 — intervention group
Group type: COMPARATOR
Intervention: Control group (no known CAD and normal LV perfusion and function)
Number of subjects: 86
Study 11553204 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 DM
Number of subjects: 6
Study 11553204 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 6
Study 9466103 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 20 mg
Number of subjects: 180
Study 9466103 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 2 mg
Number of subjects: 180
Study 9466103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 7929979 — intervention group
Group type: EXPERIMENTAL
Intervention: long-bar overdenture
Number of subjects: 145
Study 7929979 — intervention group
Group type: COMPARATOR
Intervention: fixed prosthesis
Number of subjects: 145
Study 2460118 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (plasma drug concentration 1.3 to 2.0 nmol l‐1)
Number of subjects: 8
Study 2460118 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem 120 mg three times daily
Number of subjects: 8
Study 30702006 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 158
Study 30702006 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Control
Number of subjects: 158
Study 29069260 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Number of subjects: 60
Study 29069260 — intervention group
Group type: COMPARATOR
Intervention: Air entrainment mask
Number of subjects: 60
Study 25256283 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 61
Study 25256283 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 61
Study 22864946 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg D-amphetamine
Number of subjects: 52
Study 22864946 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg D-amphetamine
Number of subjects: 52
Study 22864946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 21471971 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine complex (5 mg amlodipine and 25 mg hydrochlorothiazide) administered at bedtime (2200 hours)
Number of subjects: 80
Study 21471971 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine complex (5 mg amlodipine and 25 mg hydrochlorothiazide) administered in the morning (0800 hours)
Number of subjects: 80
Study 17428399 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy for house dust mite
Number of subjects: 107
Study 17428399 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy for pollen
Number of subjects: 107
Study 17428399 — intervention group
Group type: COMPARATOR
Intervention: Control group (pharmacotherapy)
Number of subjects: 107
Study 15820070 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE‐CytaBOM regimen
Number of subjects: 146
Study 15820070 — intervention group
Group type: COMPARATOR
Intervention: CHOP regimen
Number of subjects: 146
Study 12466700 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ITA
Number of subjects: 1069
Study 12466700 — intervention group
Group type: COMPARATOR
Intervention: Single ITA
Number of subjects: 1069
Study 9764882 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding for > or = 7 months
Number of subjects: 339
Study 9764882 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake (i.e. > or = 16 energy percentage)
Number of subjects: 339
Study 8562150 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy
Number of subjects: 200
Study 2669444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 22
Study 2669444 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 22
Study 1194910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpsychotic hospitalized schizophrenics
Number of subjects: 0
Study 1194910 — intervention group
Group type: COMPARATOR
Intervention: Normals
Number of subjects: 0
Study 1194910 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalized nonschizophrenics
Number of subjects: 0
Study 30269322 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin combined with synchronous radiotherapy
Number of subjects: 40
Study 30269322 — intervention group
Group type: COMPARATOR
Intervention: Direct operation
Number of subjects: 40
Study 26994516 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarolaner (Simparica™) administered at a minimum dosage of 2.0 mg/kg (range 2-4 mg/kg) on Days 0, 30, and 60
Number of subjects: 466
Study 26994516 — intervention group
Group type: COMPARATOR
Intervention: Spinosad (Comfortis® Chewable Tablets) as positive control
Number of subjects: 466
Study 26994516 — intervention group
Group type: COMPARATOR
Intervention: Fipronil (Frontline® Spot on) as positive control
Number of subjects: 466
Study 26994516 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarolaner (Simparica™) administered at a minimum dosage of 2.0 mg/kg (range 2-4 mg/kg)
Number of subjects: 466
Study 24829414 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE serum
Number of subjects: 0
Study 24829414 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to allogeneic T cells
Number of subjects: 0
Study 24829414 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN and SLE serum
Number of subjects: 0
Study 24829414 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR agonists (such as LPS)
Number of subjects: 0
Study 22323625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic finger abduction training
Number of subjects: 14
Study 22323625 — intervention group
Group type: COMPARATOR
Intervention: Visuomotor tracking training
Number of subjects: 14
Study 20221707 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeron 400 (400 mg I/ml)
Number of subjects: 60
Study 20221707 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol 300 (300 mg I/ml)
Number of subjects: 60
Study 20221707 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 60
Study 18556560 — intervention group
Group type: EXPERIMENTAL
Intervention: Updating training for 5 weeks
Number of subjects: 0
Study 18556560 — intervention group
Group type: EXPERIMENTAL
Intervention: Updating training
Number of subjects: 0
Study 18556560 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention
Number of subjects: 0
Study 15972319 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.86% glucose
Number of subjects: 8
Study 15972319 — intervention group
Group type: COMPARATOR
Intervention: 1.36% glucose
Number of subjects: 8
Study 15972319 — intervention group
Group type: COMPARATOR
Intervention: 7.5% icodextrin
Number of subjects: 8
Study 12837192 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved percutaneous tracheostomy
Number of subjects: 107
Study 12837192 — intervention group
Group type: COMPARATOR
Intervention: Old technique of percutaneous tracheostomy
Number of subjects: 107
Study 11026855 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Subtraction Angiography (DSA)
Number of subjects: 75
Study 11026855 — intervention group
Group type: COMPARATOR
Intervention: Bolus Chasing Angiography (BCA)
Number of subjects: 75
Study 8795677 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 5
Study 8795677 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 5
Study 1374724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-fluorouracil (5-FU) administered as adjuvant treatment following liver resection (7 patients)
Number of subjects: 25
Study 1374724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal 5-fluorouracil (5-FU) administered as palliative chemotherapy (13 patients)
Number of subjects: 25
Study 6375873 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent metoclopramide and aspirin (Migravess) 650 mg and 10 mg
Number of subjects: 118
Study 6375873 — intervention group
Group type: COMPARATOR
Intervention: Effervescent aspirin 650 mg (Alka-Seltzer)
Number of subjects: 118
Study 6375873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 6375873 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent metoclopramide and aspirin (Migravess)
Number of subjects: 118
Study 6375873 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent metoclopramide and aspirin (Migravess) vs Effervescent aspirin
Number of subjects: 118
Study 31686981 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lipid indicators (BLIs) including triglyceride (TG) level, TG/high-density lipoprotein cholesterol (HDL-C) ratio, and total cholesterol (TC)/HDL-C ratio.
Number of subjects: 969
Study 31686981 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lipid indicators (BLIs) correlated to insulin resistance (IR).
Number of subjects: 969
Study 31686981 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of indicators with diagnostic value for IR.
Number of subjects: 969
Study 29888275 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan (Azil) as add-on treatment with Methotrexate (MTX) for 90 days
Number of subjects: 64
Study 29888275 — intervention group
Group type: COMPARATOR
Intervention: Placebo with Methotrexate (MTX) for 90 days
Number of subjects: 64
Study 25957615 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidification (HH) with heated breathing tube
Number of subjects: 72
Study 25957615 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated humidification (HH)
Number of subjects: 72
Study 25957615 — intervention group
Group type: COMPARATOR
Intervention: No heated humidification (Control)
Number of subjects: 72
Study 24471516 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor intermittent training program (3 sessions of 60 min/week for 12 weeks)
Number of subjects: 105
Study 22035805 — intervention group
Group type: EXPERIMENTAL
Intervention: XEN402 (400mg twice daily)
Number of subjects: 4
Study 22035805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 20705157 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg DRSP/30 mcg EE (Yasmin)
Number of subjects: 40
Study 20705157 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg CMA/30 mcg EE (Belara)
Number of subjects: 40
Study 20705157 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mcg GSD/30 mcg EE (Minulet)
Number of subjects: 40
Study 20705157 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mcg DSG/30 mcg EE (Practil 21)
Number of subjects: 40
Study 17400976 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate‐release oxycodone 5 mg and acetaminophen 325 mg (Percocet‐5) four times daily
Number of subjects: 120
Study 17400976 — intervention group
Group type: COMPARATOR
Intervention: Controlled‐release oxycodone 10 mg (OxyContin) every 12 hr and placebo twice daily
Number of subjects: 120
Study 16267322 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg at weeks 0, 4, and 8
Number of subjects: 1244
Study 16267322 — intervention group
Group type: COMPARATOR
Intervention: Placebo at weeks 0, 4, and 8
Number of subjects: 1244
Study 16267322 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg every four weeks through week 56
Number of subjects: 1244
Study 16267322 — intervention group
Group type: COMPARATOR
Intervention: Placebo every four weeks through week 56
Number of subjects: 1244
Study 12122550 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women
Number of subjects: 83
Study 12122550 — intervention group
Group type: COMPARATOR
Intervention: Reference women
Number of subjects: 83
Study 12122550 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study 10523328 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss induced by 12 weeks of caloric restriction in obese hypertensive men
Number of subjects: 75
Study 10523328 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss induced by 12 weeks of caloric restriction in obese normotensive men
Number of subjects: 75
Study 7880708 — intervention group
Group type: EXPERIMENTAL
Intervention: 51W89 (80 micrograms kg-1)
Number of subjects: 68
Study 7880708 — intervention group
Group type: EXPERIMENTAL
Intervention: 51W89 (incremental doses of 94 (19) micrograms kg-1)
Number of subjects: 68
Study 7880708 — intervention group
Group type: EXPERIMENTAL
Intervention: 51W89
Number of subjects: 68
Study 1920787 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of buprenorphine at 0.2 mg.24 hr‐1
Number of subjects: 20
Study 1920787 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of pethidine at 50 mg.hr‐1
Number of subjects: 20
Study 1920787 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 20
Study 6811447 — intervention group
Group type: EXPERIMENTAL
Intervention: procetofen (300‐600 mg daily) for 6 months
Number of subjects: 33
Study 30667285 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally Adapted Treatment (CAT)
Number of subjects: 61
Study 30667285 — intervention group
Group type: COMPARATOR
Intervention: Standard Evidence-Based Treatment (EBT)
Number of subjects: 61
Study 31220121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dual task gait training (CDTT)
Number of subjects: 18
Study 31220121 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor dual task gait training (MDTT)
Number of subjects: 18
Study 31220121 — intervention group
Group type: COMPARATOR
Intervention: General gait training (control)
Number of subjects: 18
Study 29313875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 145
Study 29313875 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial intervention
Number of subjects: 145
Study 29313875 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 145
Study 26757463 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen Fecal Microbiota Transplantation (FMT)
Number of subjects: 232
Study 26757463 — intervention group
Group type: COMPARATOR
Intervention: Fresh Fecal Microbiota Transplantation (FMT)
Number of subjects: 232
Study 22915624 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous abatacept (∼10 mg/kg)
Number of subjects: 50
Study 22915624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21505147 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (0.08 mg·kg(‐1)·day(‐1) for 10 wk)
Number of subjects: 7
Study 21505147 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin (initial dose: 0.08 mg·kg(‐1)·day(‐1) for 3 mo, increased to 0.12 mg·kg(‐1)·day(‐1) if menstruation did not occur)
Number of subjects: 7
Study 21505147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 18351303 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 88
Study 18351303 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 88
Study 18351303 — intervention group
Group type: COMPARATOR
Intervention: 0.75% ropivacaine
Number of subjects: 88
Study 18351303 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine
Number of subjects: 88
Study 18351303 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 88
Study 18351303 — intervention group
Group type: COMPARATOR
Intervention: 0.2% ropivacaine
Number of subjects: 88
Study 18351303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative anesthesia demand
Number of subjects: 88
Study 18351303 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety parameters
Number of subjects: 88
Study 16849930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng
Number of subjects: 0
Study 16849930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14687826 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 40
Study 10741768 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 10741768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9333110 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day orally for 10 days)
Number of subjects: 8
Study 9333110 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine (0.11 mg/kg orally) after paroxetine pretreatment
Number of subjects: 8
Study 9333110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8471404 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg day‐1)
Number of subjects: 24
Study 8471404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg day‐1)
Number of subjects: 24
Study 8471404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3780837 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 6
Study 3780837 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 6
Study 28958082 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity promoting intervention (multicomponent, individually tailored; includes group sessions, individual exercise, serious games training, competence training for staff)
Number of subjects: 143
Study 28958082 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity promoting intervention
Number of subjects: 143
Study 28958082 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study 26657657 — intervention group
Group type: EXPERIMENTAL
Intervention: BEV-CAP
Number of subjects: 277
Study 24614125 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum citrulline (CIT)
Number of subjects: 26
Study 22306121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treated-initial (n=600)
Number of subjects: 853
Study 22306121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab treated-XO (n=190)
Number of subjects: 853